This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
20 Oct 2011

Korea's SK Inks R&D Pact with Chinese Biopharmaceutical Company

Two Asian companies have agreed to complete the preclinical testing of SKL-PSY within two years with an IND application filing in China by Medicilon and in the US by SK biopharmaceuticals.

South Korean biotech SK biopharmaceuticals announced Tuesday their research and development agreement with Shanghai-based Medicilon, for their novel new small molecule SKL-PSY for the treatment of depression and bipolar disorder.

 

SK biopharmaceuticals and Medicilon have agreed to complete the preclinical testing of SKL-PSY within two years with an Investigational New Drug (IND) application filing in China by Medicilon and in the United States by SK biopharmaceuticals.

 

Unlike currently-marketed antidepressants that can require 2-4 weeks to become effective, SKL-PSY has a relatively quick onset of therapeutic effects in animal models of depressive and manic states. The molecule is expected to be effective for both; such dual-action can be problemat

Related News